Author:
Manyanga Jimmy,Ganapathy Vengatesh,Bouharati Célia,Mehta Toral,Sadhasivam Balaji,Acharya Pawan,Zhao Daniel,Queimado Lurdes
Abstract
AbstractTobacco smoking is the leading preventable cause of cancer. Moreover, continued smoking during cancer therapy reduces overall survival. Aware of the negative consequences of tobacco smoking and the challenges of smoking cessation, cancer patients are inquiring whether they should switch to electronic cigarettes (e-cigarettes). To obtain evidence-based data to inform this decision, we examined the effects of e-cigarette aerosol exposure on cisplatin resistance in head and neck cancer cells. Our results show that cancer cells exposed to e-cigarette aerosol extracts and treated with cisplatin have a significant decrease in cell death, increase in viability, and increase in clonogenic survival when compared to non-exposed cells. Moreover, exposure to e-cigarette aerosol extracts increased the concentration of cisplatin needed to induce a 50% reduction in cell growth (IC50) in a nicotine-independent manner. Tobacco smoke extracts induced similar increases in cisplatin resistance. Changes in the expression of drug influx and efflux transporters, rather than activation of cell growth-promoting pathways or DNA damage repair, contribute to e-cigarette induced cisplatin resistance. These results suggest that like combustible tobacco, e-cigarette use might increase chemotherapy resistance, and emphasize the urgent need for rigorous evaluation of e-cigarettes health effects to ensure evidence-based public health policies.
Funder
National Cancer Institute, National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference73 articles.
1. Organization, W. H. Oral Cancer, https://www.who.int/cancer/prevention/diagnosis-screening/oral-cancer/en/ (2020).
2. SEER & Institute, N. C. (National Institutes of Health, https://seer.cancer.gov/csr/1975_2015/, 2018).
3. Pignon, J. P., le Maitre, A., Maillard, E., Bourhis, J. & Group, M.-N.C. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92, 4–14. https://doi.org/10.1016/j.radonc.2009.04.014 (2009).
4. Furness, S. et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD006386.pub3 (2011).
5. Petrelli, F. et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol. 50, 1041–1048. https://doi.org/10.1016/j.oraloncology.2014.08.005 (2014).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献